ReviewVirchows Archiv : an international journal of pathology2022
Incorporation of TILs in daily breast cancer care: how much evidence can we bear?
Review in Virchows Archiv : an international journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- AI-assisted image analysis of tumor-infiltrating lymphocytes as a prognostic marker in chemotherapy-naïve luminal breast cancer.NPJ breast cancer · 2026Article
- A multigene model for response stratification to neoadjuvant chemotherapy in triple negative breast cancer.Breast (Edinburgh, Scotland) · 2026Article
- Molecular profile of residual triple-negative breast cancer: opportunities for post-neoadjuvant therapeutic interventions.NPJ breast cancer · 2026Article
- Level of estrogen receptor expression, histological grade, and computationally assessed stromal TILs on pre-treatment biopsies predict pathological complete response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer.Virchows Archiv : an international journal of pathology · 2026Article
- Role of tumor‑infiltrating lymphocytes and miR‑155 in breast cancer: Insights into carcinogenesis and their potential as prognostic biomarkers (Review).Oncology reports · 2026Review
- The spatial immune landscape predicts outcome and reveals the central role of tumor-associated macrophages in inflammatory breast cancer biology.Breast cancer research : BCR · 2026Article
- AI assessment of tumor-infiltrating lymphocytes on routine H&E-slides as a predictor of response to neoadjuvant therapy in breast cancer-a real-world study.Virchows Archiv : an international journal of pathology · 2025Article
- Targeting low-risk triple-negative breast cancer: a review on de-escalation strategies for a new era.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Review
- Enhancing AI Research for Breast Cancer: A Comprehensive Review of Tumor-Infiltrating Lymphocyte Datasets.Journal of imaging informatics in medicine · 2024Review
- Inverse correlation between the amounts of lymphocytic infiltrate and stroma in breast carcinoma.Heliyon · 2024Article
- Article
- Investigation of the Relationship Between Tumor Microenvironment and Prognostic Parameters in Invasive Breast Carcinomas of No Special Type: A Retrospective Analysis.Turk patoloji dergisi · 2024Article
- Article
- Cancer immune exclusion: breaking the barricade for a successful immunotherapy.Frontiers in oncology · 2023Review
- Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies.NPJ breast cancer · 2022Article
- Review
- Article
- The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy.International journal of breast cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the most important developments in the breast cancer field has been an improved understanding of prognostic and predictive biomarkers, of which TILs are increasingly gaining importance. The evaluation of TILs by light microscopy on a H&E-stained section is workable in a daily practice setting. Reproducibility of reporting TILs is good, but heterogeneity is a cause of variation. TILs provide clinicians with important prognostic information for patients with TNBC, as early-stage TNBC with high TILs have > 98% 5-year survival and TILs predict benefit to immunotherapy. Importantly, while TILs do not have level of evidence IA, TILs should be used as a prognostic factor with caution and with other accepted prognostic variables, such as tumour size and lymph node status, to inform clinicians and patients on their treatment options. A framework on how to use the TILs in daily practice is proposed, including a co-assessment with PD-L1 for its predictive role to immunotherapy.
Indexed as
Identifiers
35043236What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.